World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
52604
World Ranking
10256
National Ranking
319

Overview

Julien Mazieres is affiliated with Paul Sabatier University in France and has contributed extensively to the field of medicine, focusing primarily on pulmonary and respiratory medicine, oncology, and cancer research. Their scholarly output encompasses a broad range of topics related to lung cancer treatments, mutations, and diagnostics, alongside work in cancer immunotherapy and biomarkers.

The scientist's recent publications include the following notable papers:

  • First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer, 2020, New England Journal of Medicine
  • Trastuzumab Deruxtecan in HER2 -Mutant Non-Small-Cell Lung Cancer, 2021, New England Journal of Medicine
  • Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations, 2020, New England Journal of Medicine
  • Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study, 2020, Journal of Clinical Oncology
  • COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study, 2020, The Lancet Oncology

Mazieres collaborates frequently with several researchers within the oncology and respiratory fields. The most common co-authors include:

  • Enriqueta Felip
  • Fabrice Barlési
  • Benjamin Besse
  • Alexis B. Cortot
  • Denis Moro-Sibilot

Their publications appear predominantly in established journals, reflecting consistent research engagement in lung cancer and related fields. Frequent publication venues include:

  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Revue des Maladies Respiratoires Actualités
  • Lung Cancer

Julien Mazieres's research spans multiple interconnected fields of study:

  • Medicine
  • Pulmonary and Respiratory Medicine
  • Oncology
  • Cancer Research
  • Molecular Biology
  • Surgery

Their research topics reflect a strong emphasis on the clinical and molecular aspects of lung cancer, cancer biomarkers, and genomics. Main topics they focus on include:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • HER2/EGFR in Cancer Research

Best Publications

  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

    Rafael Rosell;Enric Carcereny;Radj Gervais;Alain Vergnenegre

  • Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

    Luis Paz-Ares;Alexander Luft;David Vicente;Ali Tafreshi

  • Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial

    Louis Fehrenbacher;Alexander Spira;Marcus Ballinger;Marcin Kowanetz

  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe

  • Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

    David Planchard;Egbert F Smit;Harry J M Groen;Julien Mazieres

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

    Fabrice Barlesi;Julien Mazieres;Jean-Philippe Merlio;Didier Debieuvre

  • Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

    Gérard Zalcman;Gérard Zalcman;Julien Mazieres;Jacques Margery;Laurent Greillier

  • Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

    Laura Mezquita;Edouard Auclin;Roberto Ferrara;Melinda Charrier

  • An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

    David Planchard;Benjamin Besse;Harry J M Groen;Pierre-Jean Souquet

  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Todd M. Bauer;Filippo de Marinis;Enriqueta Felip

  • Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

    Julien Mazières;Solange Peters;Benoit Lepage;Alexis B. Cortot

  • Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

    Roberto Ferrara;Laura Mezquita;Matthieu Texier;Jihene Lahmar

  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Paul K. Paik;Enriqueta Felip;Remi Veillon;Hiroshi Sakai

  • Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

    Bob T Li;Egbert F Smit;Yasushi Goto;Kazuhiko Nakagawa

  • COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.

    Marina Chiara Garassino;Jennifer G. Whisenant;Li Ching Huang;Annalisa Trama

  • Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

    Charles M Rudin;Mark M Awad;Alejandro Navarro;Maya Gottfried

  • A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

    Luis Paz-Ares;David Vicente;Ali Tafreshi;Andrew Robinson

  • Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

    Arnaud Scherpereel;Julien Mazieres;Laurent Greillier;Sylvie Lantuejoul

  • Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

    David Planchard;Tae Min Kim;Julien Mazieres;Elisabeth Quoix

Frequent Co-Authors

Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
Benjamin Besse
Benjamin Besse University of Paris-Saclay
Jacques Cadranel
Jacques Cadranel Université Paris Cité
Nicolas Girard
Nicolas Girard Institute Curie
David Planchard
David Planchard Institut Gustave Roussy
Silvia Novello
Silvia Novello University of Turin
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
David M. Jablons
David M. Jablons University of California, San Francisco
Jean-Charles Soria
Jean-Charles Soria Amgen (United States)
Martin Reck
Martin Reck LungenClinic Grosshansdorf

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens the door to numerous related online degrees and flexible career options, whether you are beginning or advancing your healthcare journey. Many students are searching for high-quality programs that balance cost, convenience, and future job prospects.

If your interest extends to healthcare leadership, consider enrolling in one of the cheapest MHA programs to pursue a master’s in healthcare administration online. For nursing professionals aiming for the next level, a 1 year DNP program online can offer an accelerated path to a Doctor of Nursing Practice without long campus commitments.

Pharmacists or students considering pharmacy can now earn their doctorate from home through accredited online Pharm D programs. Meanwhile, the IT side of healthcare is growing fast; a health information management degree online can prepare you for roles managing patient information and technology in medical settings.

These online degrees support a range of career trajectories and can help you enter or advance in the healthcare sector from wherever you are.

Best Scientists Citing Julien Mazieres

Trending Scientists